RxDoctor Payments Data

Michelle Endicott, DO

Dermatology · South Charleston, WVNPI 1699774315

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.9% of the total across 209 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 19 manufacturers reported payments, led by AbbVie at 31.6% of the total.

$3,514in general payments, 2019–2025

Across 209 payments — averaging $16.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$490
  • Lilly USA, LLC$436
  • Regeneron Healthcare Solutions, Inc.$427
  • UCB, Inc.$253
  • Dermavant Sciences, Inc.$228
  • plus $570 from 13 others

What the payments were for

  • Food & beverage$3,29994%
  • Education$2156%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,514 in reported general payments places this provider in the 55th percentile of 39 dermatology providers in West Virginia.

See all dermatology providers in West Virginia

Medicare billing

Part B allowed, 2024
$307,432
Medicare patients
869
Services billed
5,078

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TremfyaGuselkumab28$391,210
Skyrizi PenRisankizumab-Rzaa15$328,204
Humira(Cf) PenAdalimumab23$254,962
OtezlaApremilast37$188,929
Cosentyx Sensoready (2 Pens)Secukinumab25$185,303
Dupixent PenDupilumab29$129,115
Taltz AutoinjectorIxekizumab14$99,444
Dupixent SyringeDupilumab16$62,677
Clobetasol Propionate345$12,455
Acitretin24$11,225
Fluorouracil195$10,812
Doxycycline Hyclate219$5,474
Metronidazole53$4,177
Ivermectin19$3,843
Ketoconazole225$3,840

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonTremfya$490$391,21028 claims
AmgenOtezla$61$188,92937 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 39 dermatology providers in West Virginia.

Other dermatology in South Charleston

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →